Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8+ T cell cytotoxicity over BEMPEG+RT

Por William L Redmond, Annah S Rolig, Daniel C Rose, Saul Kivimae, Werner Rubas, Grace Helen McGee
Publicado em 2022-04-01